Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Paroxysmal Choreoathetosis Market

ID: MRFR/HC/38718-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Paroxysmal Choreoathetosis Market Research Report: Size, Share, Trend Analysis By Types (Genetic Paroxysmal Choreoathetosis, Acquired Paroxysmal Choreoathetosis, Syndromic Paroxysmal Choreoathetosis), By Symptoms (Chorea, Athetosis, Dystonia, Dysarthria), By Age Group (Pediatric, Adult, Geriatric), By Treatment Type (Pharmacological Treatments, Physical Therapy, Occupational Therapy, Speech Therapy) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Paroxysmal Choreoathetosis Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type (USD Million)
  49.     4.1.1 Genetic Paroxysmal Choreoathetosis
  50.     4.1.2 Acquired Paroxysmal Choreoathetosis
  51.     4.1.3 Syndromic Paroxysmal Choreoathetosis
  52.   4.2 Healthcare, BY Symptoms (USD Million)
  53.     4.2.1 Chorea
  54.     4.2.2 Athetosis
  55.     4.2.3 Dystonia
  56.     4.2.4 Dysarthria
  57.   4.3 Healthcare, BY Age Group (USD Million)
  58.     4.3.1 Pediatric
  59.     4.3.2 Adult
  60.     4.3.3 Geriatric
  61.   4.4 Healthcare, BY Treatment Type (USD Million)
  62.     4.4.1 Pharmacological Treatments
  63.     4.4.2 Physical Therapy
  64.     4.4.3 Occupational Therapy
  65.     4.4.4 Speech Therapy
  66.   4.5 Healthcare, BY Region (USD Million)
  67.     4.5.1 North America
  68.       4.5.1.1 US
  69.       4.5.1.2 Canada
  70.     4.5.2 Europe
  71.       4.5.2.1 Germany
  72.       4.5.2.2 UK
  73.       4.5.2.3 France
  74.       4.5.2.4 Russia
  75.       4.5.2.5 Italy
  76.       4.5.2.6 Spain
  77.       4.5.2.7 Rest of Europe
  78.     4.5.3 APAC
  79.       4.5.3.1 China
  80.       4.5.3.2 India
  81.       4.5.3.3 Japan
  82.       4.5.3.4 South Korea
  83.       4.5.3.5 Malaysia
  84.       4.5.3.6 Thailand
  85.       4.5.3.7 Indonesia
  86.       4.5.3.8 Rest of APAC
  87.     4.5.4 South America
  88.       4.5.4.1 Brazil
  89.       4.5.4.2 Mexico
  90.       4.5.4.3 Argentina
  91.       4.5.4.4 Rest of South America
  92.     4.5.5 MEA
  93.       4.5.5.1 GCC Countries
  94.       4.5.5.2 South Africa
  95.       4.5.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 AstraZeneca (GB)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Novartis (CH)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Pfizer (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Bristol-Myers Squibb (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Roche (CH)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 Sanofi (FR)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Teva Pharmaceutical Industries (IL)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Eli Lilly and Company (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 AbbVie (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY TYPE
  173.   6.4 US MARKET ANALYSIS BY SYMPTOMS
  174.   6.5 US MARKET ANALYSIS BY AGE GROUP
  175.   6.6 US MARKET ANALYSIS BY TREATMENT TYPE
  176.   6.7 CANADA MARKET ANALYSIS BY TYPE
  177.   6.8 CANADA MARKET ANALYSIS BY SYMPTOMS
  178.   6.9 CANADA MARKET ANALYSIS BY AGE GROUP
  179.   6.10 CANADA MARKET ANALYSIS BY TREATMENT TYPE
  180.   6.11 EUROPE MARKET ANALYSIS
  181.   6.12 GERMANY MARKET ANALYSIS BY TYPE
  182.   6.13 GERMANY MARKET ANALYSIS BY SYMPTOMS
  183.   6.14 GERMANY MARKET ANALYSIS BY AGE GROUP
  184.   6.15 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
  185.   6.16 UK MARKET ANALYSIS BY TYPE
  186.   6.17 UK MARKET ANALYSIS BY SYMPTOMS
  187.   6.18 UK MARKET ANALYSIS BY AGE GROUP
  188.   6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
  189.   6.20 FRANCE MARKET ANALYSIS BY TYPE
  190.   6.21 FRANCE MARKET ANALYSIS BY SYMPTOMS
  191.   6.22 FRANCE MARKET ANALYSIS BY AGE GROUP
  192.   6.23 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
  193.   6.24 RUSSIA MARKET ANALYSIS BY TYPE
  194.   6.25 RUSSIA MARKET ANALYSIS BY SYMPTOMS
  195.   6.26 RUSSIA MARKET ANALYSIS BY AGE GROUP
  196.   6.27 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
  197.   6.28 ITALY MARKET ANALYSIS BY TYPE
  198.   6.29 ITALY MARKET ANALYSIS BY SYMPTOMS
  199.   6.30 ITALY MARKET ANALYSIS BY AGE GROUP
  200.   6.31 ITALY MARKET ANALYSIS BY TREATMENT TYPE
  201.   6.32 SPAIN MARKET ANALYSIS BY TYPE
  202.   6.33 SPAIN MARKET ANALYSIS BY SYMPTOMS
  203.   6.34 SPAIN MARKET ANALYSIS BY AGE GROUP
  204.   6.35 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
  205.   6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
  206.   6.37 REST OF EUROPE MARKET ANALYSIS BY SYMPTOMS
  207.   6.38 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
  208.   6.39 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
  209.   6.40 APAC MARKET ANALYSIS
  210.   6.41 CHINA MARKET ANALYSIS BY TYPE
  211.   6.42 CHINA MARKET ANALYSIS BY SYMPTOMS
  212.   6.43 CHINA MARKET ANALYSIS BY AGE GROUP
  213.   6.44 CHINA MARKET ANALYSIS BY TREATMENT TYPE
  214.   6.45 INDIA MARKET ANALYSIS BY TYPE
  215.   6.46 INDIA MARKET ANALYSIS BY SYMPTOMS
  216.   6.47 INDIA MARKET ANALYSIS BY AGE GROUP
  217.   6.48 INDIA MARKET ANALYSIS BY TREATMENT TYPE
  218.   6.49 JAPAN MARKET ANALYSIS BY TYPE
  219.   6.50 JAPAN MARKET ANALYSIS BY SYMPTOMS
  220.   6.51 JAPAN MARKET ANALYSIS BY AGE GROUP
  221.   6.52 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
  222.   6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
  223.   6.54 SOUTH KOREA MARKET ANALYSIS BY SYMPTOMS
  224.   6.55 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
  225.   6.56 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
  226.   6.57 MALAYSIA MARKET ANALYSIS BY TYPE
  227.   6.58 MALAYSIA MARKET ANALYSIS BY SYMPTOMS
  228.   6.59 MALAYSIA MARKET ANALYSIS BY AGE GROUP
  229.   6.60 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
  230.   6.61 THAILAND MARKET ANALYSIS BY TYPE
  231.   6.62 THAILAND MARKET ANALYSIS BY SYMPTOMS
  232.   6.63 THAILAND MARKET ANALYSIS BY AGE GROUP
  233.   6.64 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
  234.   6.65 INDONESIA MARKET ANALYSIS BY TYPE
  235.   6.66 INDONESIA MARKET ANALYSIS BY SYMPTOMS
  236.   6.67 INDONESIA MARKET ANALYSIS BY AGE GROUP
  237.   6.68 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
  238.   6.69 REST OF APAC MARKET ANALYSIS BY TYPE
  239.   6.70 REST OF APAC MARKET ANALYSIS BY SYMPTOMS
  240.   6.71 REST OF APAC MARKET ANALYSIS BY AGE GROUP
  241.   6.72 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
  242.   6.73 SOUTH AMERICA MARKET ANALYSIS
  243.   6.74 BRAZIL MARKET ANALYSIS BY TYPE
  244.   6.75 BRAZIL MARKET ANALYSIS BY SYMPTOMS
  245.   6.76 BRAZIL MARKET ANALYSIS BY AGE GROUP
  246.   6.77 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
  247.   6.78 MEXICO MARKET ANALYSIS BY TYPE
  248.   6.79 MEXICO MARKET ANALYSIS BY SYMPTOMS
  249.   6.80 MEXICO MARKET ANALYSIS BY AGE GROUP
  250.   6.81 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
  251.   6.82 ARGENTINA MARKET ANALYSIS BY TYPE
  252.   6.83 ARGENTINA MARKET ANALYSIS BY SYMPTOMS
  253.   6.84 ARGENTINA MARKET ANALYSIS BY AGE GROUP
  254.   6.85 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
  255.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  256.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SYMPTOMS
  257.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
  258.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  259.   6.90 MEA MARKET ANALYSIS
  260.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  261.   6.92 GCC COUNTRIES MARKET ANALYSIS BY SYMPTOMS
  262.   6.93 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
  263.   6.94 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
  264.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  265.   6.96 SOUTH AFRICA MARKET ANALYSIS BY SYMPTOMS
  266.   6.97 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
  267.   6.98 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
  268.   6.99 REST OF MEA MARKET ANALYSIS BY TYPE
  269.   6.100 REST OF MEA MARKET ANALYSIS BY SYMPTOMS
  270.   6.101 REST OF MEA MARKET ANALYSIS BY AGE GROUP
  271.   6.102 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
  272.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  273.   6.104 RESEARCH PROCESS OF MRFR
  274.   6.105 DRO ANALYSIS OF HEALTHCARE
  275.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  276.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  277.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  278.   6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  279.   6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
  280.   6.111 HEALTHCARE, BY SYMPTOMS, 2024 (% SHARE)
  281.   6.112 HEALTHCARE, BY SYMPTOMS, 2024 TO 2035 (USD Million)
  282.   6.113 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
  283.   6.114 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
  284.   6.115 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  285.   6.116 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
  286.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  287. 7 LIST OF TABLES
  288.   7.1 LIST OF ASSUMPTIONS
  289.     7.1.1
  290.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  291.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  292.     7.2.2 BY SYMPTOMS, 2025-2035 (USD Million)
  293.     7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
  294.     7.2.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  295.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  296.     7.3.1 BY TYPE, 2025-2035 (USD Million)
  297.     7.3.2 BY SYMPTOMS, 2025-2035 (USD Million)
  298.     7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
  299.     7.3.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  300.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  301.     7.4.1 BY TYPE, 2025-2035 (USD Million)
  302.     7.4.2 BY SYMPTOMS, 2025-2035 (USD Million)
  303.     7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
  304.     7.4.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  305.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.5.1 BY TYPE, 2025-2035 (USD Million)
  307.     7.5.2 BY SYMPTOMS, 2025-2035 (USD Million)
  308.     7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
  309.     7.5.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  310.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  311.     7.6.1 BY TYPE, 2025-2035 (USD Million)
  312.     7.6.2 BY SYMPTOMS, 2025-2035 (USD Million)
  313.     7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
  314.     7.6.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  315.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  316.     7.7.1 BY TYPE, 2025-2035 (USD Million)
  317.     7.7.2 BY SYMPTOMS, 2025-2035 (USD Million)
  318.     7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
  319.     7.7.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  320.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  321.     7.8.1 BY TYPE, 2025-2035 (USD Million)
  322.     7.8.2 BY SYMPTOMS, 2025-2035 (USD Million)
  323.     7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
  324.     7.8.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  325.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  326.     7.9.1 BY TYPE, 2025-2035 (USD Million)
  327.     7.9.2 BY SYMPTOMS, 2025-2035 (USD Million)
  328.     7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
  329.     7.9.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  330.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  331.     7.10.1 BY TYPE, 2025-2035 (USD Million)
  332.     7.10.2 BY SYMPTOMS, 2025-2035 (USD Million)
  333.     7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
  334.     7.10.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  335.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  336.     7.11.1 BY TYPE, 2025-2035 (USD Million)
  337.     7.11.2 BY SYMPTOMS, 2025-2035 (USD Million)
  338.     7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
  339.     7.11.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  340.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  341.     7.12.1 BY TYPE, 2025-2035 (USD Million)
  342.     7.12.2 BY SYMPTOMS, 2025-2035 (USD Million)
  343.     7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
  344.     7.12.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  345.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  346.     7.13.1 BY TYPE, 2025-2035 (USD Million)
  347.     7.13.2 BY SYMPTOMS, 2025-2035 (USD Million)
  348.     7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
  349.     7.13.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  350.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  351.     7.14.1 BY TYPE, 2025-2035 (USD Million)
  352.     7.14.2 BY SYMPTOMS, 2025-2035 (USD Million)
  353.     7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
  354.     7.14.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  355.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  356.     7.15.1 BY TYPE, 2025-2035 (USD Million)
  357.     7.15.2 BY SYMPTOMS, 2025-2035 (USD Million)
  358.     7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
  359.     7.15.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  360.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  361.     7.16.1 BY TYPE, 2025-2035 (USD Million)
  362.     7.16.2 BY SYMPTOMS, 2025-2035 (USD Million)
  363.     7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
  364.     7.16.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  365.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  366.     7.17.1 BY TYPE, 2025-2035 (USD Million)
  367.     7.17.2 BY SYMPTOMS, 2025-2035 (USD Million)
  368.     7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
  369.     7.17.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  370.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  371.     7.18.1 BY TYPE, 2025-2035 (USD Million)
  372.     7.18.2 BY SYMPTOMS, 2025-2035 (USD Million)
  373.     7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
  374.     7.18.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  375.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  376.     7.19.1 BY TYPE, 2025-2035 (USD Million)
  377.     7.19.2 BY SYMPTOMS, 2025-2035 (USD Million)
  378.     7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
  379.     7.19.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  380.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  381.     7.20.1 BY TYPE, 2025-2035 (USD Million)
  382.     7.20.2 BY SYMPTOMS, 2025-2035 (USD Million)
  383.     7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
  384.     7.20.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  385.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  386.     7.21.1 BY TYPE, 2025-2035 (USD Million)
  387.     7.21.2 BY SYMPTOMS, 2025-2035 (USD Million)
  388.     7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
  389.     7.21.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  390.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  391.     7.22.1 BY TYPE, 2025-2035 (USD Million)
  392.     7.22.2 BY SYMPTOMS, 2025-2035 (USD Million)
  393.     7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
  394.     7.22.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  395.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  396.     7.23.1 BY TYPE, 2025-2035 (USD Million)
  397.     7.23.2 BY SYMPTOMS, 2025-2035 (USD Million)
  398.     7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
  399.     7.23.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  400.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  401.     7.24.1 BY TYPE, 2025-2035 (USD Million)
  402.     7.24.2 BY SYMPTOMS, 2025-2035 (USD Million)
  403.     7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
  404.     7.24.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  405.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  406.     7.25.1 BY TYPE, 2025-2035 (USD Million)
  407.     7.25.2 BY SYMPTOMS, 2025-2035 (USD Million)
  408.     7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
  409.     7.25.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  410.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  411.     7.26.1 BY TYPE, 2025-2035 (USD Million)
  412.     7.26.2 BY SYMPTOMS, 2025-2035 (USD Million)
  413.     7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
  414.     7.26.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  415.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  416.     7.27.1 BY TYPE, 2025-2035 (USD Million)
  417.     7.27.2 BY SYMPTOMS, 2025-2035 (USD Million)
  418.     7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
  419.     7.27.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  420.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  421.     7.28.1 BY TYPE, 2025-2035 (USD Million)
  422.     7.28.2 BY SYMPTOMS, 2025-2035 (USD Million)
  423.     7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
  424.     7.28.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  425.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  426.     7.29.1 BY TYPE, 2025-2035 (USD Million)
  427.     7.29.2 BY SYMPTOMS, 2025-2035 (USD Million)
  428.     7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
  429.     7.29.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  430.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  431.     7.30.1 BY TYPE, 2025-2035 (USD Million)
  432.     7.30.2 BY SYMPTOMS, 2025-2035 (USD Million)
  433.     7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
  434.     7.30.4 BY TREATMENT TYPE, 2025-2035 (USD Million)
  435.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  436.     7.31.1
  437.   7.32 ACQUISITION/PARTNERSHIP
  438.     7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Million, 2025-2035)

  • Genetic Paroxysmal Choreoathetosis
  • Acquired Paroxysmal Choreoathetosis
  • Syndromic Paroxysmal Choreoathetosis

Healthcare By Symptoms (USD Million, 2025-2035)

  • Chorea
  • Athetosis
  • Dystonia
  • Dysarthria

Healthcare By Age Group (USD Million, 2025-2035)

  • Pediatric
  • Adult
  • Geriatric

Healthcare By Treatment Type (USD Million, 2025-2035)

  • Pharmacological Treatments
  • Physical Therapy
  • Occupational Therapy
  • Speech Therapy

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions